{"id":"azelnidipine","rwe":[],"tags":[{"label":"azelnidipine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Voltage-gated L-type calcium channel","category":"target"},{"label":"CACNA1C","category":"gene"},{"label":"CACNA1D","category":"gene"},{"label":"Active","category":"status"},{"label":"Hypertensive disorder","category":"indication"}],"phase":"phase_3","safety":{"safetySignals":[{"llr":74.973,"date":"","count":30,"signal":"Cerebral infarction","source":"DrugCentral FAERS","actionTaken":"Reported 30 times (LLR=75)"},{"llr":67.943,"date":"","count":32,"signal":"Hepatic function abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 32 times (LLR=68)"},{"llr":47.929,"date":"","count":34,"signal":"Renal impairment","source":"DrugCentral FAERS","actionTaken":"Reported 34 times (LLR=48)"},{"llr":39.706,"date":"","count":30,"signal":"Cardiac failure","source":"DrugCentral FAERS","actionTaken":"Reported 30 times (LLR=40)"},{"llr":32.929,"date":"","count":30,"signal":"Platelet count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 30 times (LLR=33)"},{"llr":27.334,"date":"","count":21,"signal":"Interstitial lung disease","source":"DrugCentral FAERS","actionTaken":"Reported 21 times (LLR=27)"}],"commonSideEffects":[{"effect":"Cerebral infarction","drugRate":"LLR 75","severity":"common"},{"effect":"Hepatic function abnormal","drugRate":"LLR 68","severity":"common"},{"effect":"Renal impairment","drugRate":"LLR 48","severity":"common"},{"effect":"Cardiac failure","drugRate":"LLR 40","severity":"common"},{"effect":"Platelet count decreased","drugRate":"LLR 33","severity":"common"},{"effect":"Interstitial lung disease","drugRate":"LLR 27","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"calblock","offLabel":[],"synonyms":["azelnidipine","calblock","CS-905"],"timeline":[],"brandName":"Calblock","ecosystem":[{"indication":"Hypertensive disorder","otherDrugs":[{"name":"acebutolol","slug":"acebutolol","company":"Promius Pharma"},{"name":"aliskiren","slug":"aliskiren","company":"Novartis"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"}],"globalPrevalence":null}],"mechanism":{"target":"Voltage-gated L-type calcium channel","targets":[{"gene":"CACNA1C","source":"DrugCentral","target":"Voltage-gated L-type calcium channel","protein":"Voltage-dependent L-type calcium channel subunit alpha-1C"},{"gene":"CACNA1D","source":"DrugCentral","target":"Voltage-gated L-type calcium channel","protein":"Voltage-dependent L-type calcium channel subunit alpha-1D"}],"modality":"Small Molecule","drugClass":"azelnidipine","explanation":"Imagine your blood vessels are like roads in your body. When calcium channels are open, they allow calcium to flow in and cause the roads to narrow and get congested. Calblock blocks these channels, allowing the roads to relax and widen, which helps to reduce blood pressure.","oneSentence":"Calblock works by blocking calcium channels in blood vessel walls, which helps to relax the vessels and lower blood pressure.","technicalDetail":"Calblock (azelnidipine) is a selective L-type calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle cells, leading to vasodilation and a subsequent decrease in blood pressure."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/272","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=AZELNIDIPINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AZELNIDIPINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:52:22.838279","biosimilars":[],"competitors":[{"drugName":"nicardipine","drugSlug":"nicardipine","fdaApproval":"1988-12-21","patentExpiry":"Dec 26, 2027","patentStatus":"Patent protected","relationship":"same-target"}],"genericName":"azelnidipine","indications":{"approved":[{"name":"Hypertensive disorder","source":"DrugCentral","snomedId":38341003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"nicardipine","brandName":"nicardipine","genericName":"nicardipine","approvalYear":"1988","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT00294567","phase":"PHASE4","title":"Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J)","status":"COMPLETED","sponsor":"Juntendo University","startDate":"2005-12","conditions":["Hypertension","Coronary Atherosclerosis"],"enrollment":199,"completionDate":"2011-01"},{"nctId":"NCT01819441","phase":"PHASE4","title":"Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients","status":"UNKNOWN","sponsor":"Yining Huang","startDate":"2012-05","conditions":["Cerebral Small Vessel Diseases"],"enrollment":1200,"completionDate":"2016-12"},{"nctId":"NCT01028534","phase":"NA","title":"Effects of Antihypertensive Drugs in Patients With Hypertension and Obstructive Sleep Apnea (OSA)","status":"COMPLETED","sponsor":"Kyoto University, Graduate School of Medicine","startDate":"2010-07","conditions":["Obstructive Sleep Apnea","Hypertension"],"enrollment":150,"completionDate":"2013-12"},{"nctId":"NCT00454662","phase":"PHASE4","title":"Combination of OLMesartan and CCB or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study)","status":"COMPLETED","sponsor":"COLM Study Research Organization","startDate":"2007-04","conditions":["Hypertension","Cardiovascular Disease","Diabetes"],"enrollment":5141,"completionDate":"2011-09"},{"nctId":"NCT00134160","phase":"PHASE4","title":"OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study","status":"COMPLETED","sponsor":"OSCAR Study","startDate":"2005-08","conditions":["Hypertension","Cardiovascular Diseases"],"enrollment":1000,"completionDate":"2010-05"},{"nctId":"NCT00607035","phase":"PHASE4","title":"The Japan-Combined Treatment With Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study (J-CORE)","status":"COMPLETED","sponsor":"Jichi Medical University","startDate":"2006-05","conditions":["Hypertension"],"enrollment":220,"completionDate":"2008-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"PV23P19YUG","CHEBI":"CHEBI:31247","INN_ID":"7109","UMLSCUI":"C0753287","ChEMBL_ID":"CHEMBL1275868","KEGG_DRUG":"D01145","DRUGBANK_ID":"DB09230","PUBCHEM_CID":"65948","MESH_SUPPLEMENTAL_RECORD_UI":"C061679"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Calblock (azelnidipine) is a small molecule drug that targets voltage-gated L-type calcium channels. It is used to treat hypertensive disorders by relaxing blood vessels and reducing blood pressure. The commercial status of Calblock is unknown, and it may be patented or have generic manufacturers. Key safety considerations include potential interactions with other medications and monitoring of blood pressure. Calblock is not FDA-approved, but it is approved in other countries for its indicated use.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}